Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14876942 | 1.00 | MEN1 (0.71) | MEN1KMT2AALDH1A1LMNATP53 | |
| SCHEMBL2595128 | 1.00 | MEN1 (0.71) | MEN1KMT2AALDH1A1LMNATP53 | |
| SCHEMBL4056197 | 0.88 | MEN1 (0.60) | MEN1KMT2AALDH1A1LMNATP53 | |
| SCHEMBL4056200 | 0.88 | MEN1 (0.60) | MEN1KMT2AALDH1A1LMNATP53 | |
| SCHEMBL2589796 | 0.83 | MEN1 (0.68) | MEN1KMT2AALDH1A1LMNAGAA | |
| SCHEMBL2589792 | 0.83 | MEN1 (0.68) | MEN1KMT2AALDH1A1LMNAGAA | |
| Bromide SCHEMBL11180829 | 0.81 | MEN1 (0.66) | MEN1KMT2AALDH1A1LMNAGAA | |
| SCHEMBL2587984 | 0.81 | MEN1 (0.55) | MEN1KMT2AALDH1A1LMNAGAA | |
| SCHEMBL2587982 | 0.81 | MEN1 (0.55) | MEN1KMT2AALDH1A1LMNAGAA | |
| Bromide SCHEMBL11277318 | 0.81 | MEN1 (0.66) | MEN1KMT2AALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249191-A1 | Compositions for Controlling Vascularization in Ophthalmological and Dermatological Diseases | AVIENNE PHARMACEUTICALS GMBH (AT) | 2014-09-04 | — | — | US | disclosed |
| US-20130102645-A1 | Methods and compositions for controlling vascularization in ophthalmological and dermatological diseases | AVIENNE PHARMACEUTICALS GMBH (AT) | 2013-04-25 | — | — | US | disclosed |
| WO-2011135303-A2 | UBIQUITINATION MODULATORS | ITI SCOTLAND LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102645-A1 | Methods and compositions for controlling vascularization in ophthalmological and dermatological diseases | KDR, REN, FLT1 | MEN1 2094/4885KMT2A 4438/4885ALDH1A1 1466/4885 |
| US-20140249191-A1 | Compositions for Controlling Vascularization in Ophthalmological and Dermatological Diseases | FLT1, KDR, FLT4 | MEN1 1801/4885KMT2A 4419/4885ALDH1A1 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.